FDA label f2a0bd7c-881d-37ee-e053-2995a90abccb
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- e1e08327-4b90-463e-bb2a-22438cabcef2
- SPL ID
- f2a0bd7c-881d-37ee-e053-2995a90abccb
- Version
- 5
- Effective date
- 2023-01-19
- Source export date
- 2026-09-28
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/bb1af06e95bcf9567b07e56fcf3a03c0cac3c7c82ff89d4c970881174949e5b7/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:44:30
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | f2a0bd7c-881d-37ee-e053-2995a90abccb | id | |
| spl set id | e1e08327-4b90-463e-bb2a-22438cabcef2 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS SECTION Administration of Seromycin should be discontinued or the dosage reduced if the patient develops allergic dermatitis or symptoms of CNS toxicity, such as convulsions, psychosis, somnolence, depression, confusion, hyperreflexia, headache, tremor, vertigo, paresis, or dysarthria. The toxicity of Seromycin is closely related to excessive blood levels (above 30 μg/mL), as determined by high dosage or inadequate renal clearance. The ratio of toxic dose to effective dose in tuberculosis is small. The risk of convulsions is increased in chronic alcoholics. Patients should be monitored by hematologic, renal excretion, blood level, and liver function studies.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS SECTION Most adverse reactions occruing during therapy with Seromycin® involve the nervous system or are manifestitations of drug hypersensitivity. The following side effects have been observed in patients receiving Seromycin®: Nervous system symptoms (which appear to be related to higher dosages of the drug, i.e., more than 500 mg daily) - Convulsions - Drowsiness and somnolence - Headache - Tremor - Dysarthria - Vertigo - Confusion and disorientation with loss of memory - Psychoses, possibly with suicidal tendencies - Character changes - Hyperirritability - Aggression - Paresis - Hyperreflexia - Paresthesia - Major & minor (localized) clonic seizures - Coma Cardiovascular: Sudden development of congestive heart failure in patients receiving 1 to 1.5 g of Seromycin® daily has been reported Allergy (apparently not related to dosage) Skin rash Miscellaneous: Elevated serum transaminase, especially in patients with preexisting liver disease
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.